Skip to content

HOPE Study

HOPE helps us imagine a different future.

Introducing HOPE

HOPE was our large-scale study to test how our science may help people with mild-to-moderate Alzheimer’s preserve the everyday abilities they depend on.

673 participants took part in HOPE.

Our largest clinical study included people with different levels of cognitive impairment. Researchers looked at two groups, with MMSE scores of 21–28 and 15–20, to understand how the results differed between them.

The results offered encouraging evidence that Spectris could help slow the decline in thinking, memory and everyday abilities in those with early symptomatic Alzheimer’s disease, giving people and families new reasons for hope.

At home.

One hour a day.

Non-invasive.

Shaped by what matters most to people and families.

To understand what the HOPE findings could mean for people and families, we translated clinical results into everyday life. The What Matters Most framework, created by leading Alzheimer’s advocacy organizations, helped us show the HOPE findings through the everyday abilities people value most.

Observed % slowing relative to sham

>100% slowing means absence of observed mean decline in the active group

  • General Independence 38%

  • Thought Processing 110%

  • Communication 102%

  • Daily Activities 71%

  • Social Life/Activities 116%

The everyday is everything.

The moments we share, the relationships we nurture, and the things we love doing are what make life meaningful.

Daily Activities.

Communication.

Social Life.

General Independence.

Thought Processing.

In early symptomatic Alzheimer’s disease, Spectris slowed decline in daily function and disease severity over 12 months.

Slower decline in daily function

Slower progression of disease severity

Where the science leads

Beginning with Alzheimer’s, we’re working towards better brain health for everyone.

HOPE is an important step forward for us. The most encouraging results were seen in people with early symptomatic Alzheimer’s, who followed the recommended daily routine throughout the study.

These findings give us a foundation to explore how Spectris could support brain health across different conditions and throughout life.

Learn more

Your next step with Cognito starts here.

Tell us what you’re looking for and we’ll help you find the right information or people.

Sabbagh MN, Kern RZ, Zusterzeel R, Hamilton RH. Spectris Treatment in Mild-to-Moderate Alzheimer’s Disease: Topline Results and Secondary Analyses From the HOPE Pivotal Study. Presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference; November 16-19, 2026; Boston, Massachusetts.